Ironwood Pharmaceuticals Inc. kicked off the trading day on 10/10/19 with a price increase of 1.30%, equivalent to $0.11 relative change for the day. Taking a more long-term approach, IRWD had a 52-week range of $7.59 to $14.93. At the time of this article’s publishing, this stock is trading at $8.57 after starting the trading session at $8.50. At the time of writing, this stock’s 50-day Moving Average stands at $9.15, while the 200-day Moving Average of this stock is currently $11.25.
Currently, this company’s share volume is sitting at $1064300, but has maintained average daily volume of $1.96M. This stock has generated an average Year to Date volume of $1.62 million, alongside an average 20-day volume of $1.78 million. This publicly-traded company’s shares outstanding now amounts to $155.85 million, simultaneously with a float of $152.45 million. The organization now has a market capitalization sitting at $1.34 billion.
Ironwood Pharmaceuticals Inc.(IRWD) Ownership Data
Now let’s turn our focus to how large-scale investors are behaving with this stock. Ironwood Pharmaceuticals Inc.’s current insider ownership accounts for 1.10%. According to the most recent latest insider trade that took place on Aug 30 this organization’s President exercised an option 220,000 at the rate of 4.88, making the entire transaction hit 1,073,600 in total value, affecting insider ownership by 329,739. Preceding that transaction, on Aug 30 Company’s President sold 220,000 at a price of 9.24, making the whole transaction’s value amount to 2,032,800. This particular insider is now the holder of 109,739 in total.
All together, they are the legal holders of 155.85M shares. If we focus on the top 3 stockholders for this publicly-traded organization, Wellington Management Co. LLP owns 21,727,703 shares, with Brown Capital Management LLC in 2nd place owning 17,160,781 shares and The Vanguard Group, Inc. in third place with total ownership of 15,267,247 shares.
Ironwood Pharmaceuticals Inc. (IRWD) Earnings and Revenue Data
In the latest quarterly report that this company released, which was put into the public domain on 6/29/2019, the organization reported $0.1 earnings per share (EPS) for the three-month period, surpassing the consensus estimate (set at -$0.03) by $0.13.
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.15 per share during the current fiscal year.
Ironwood Pharmaceuticals Inc.’s EPS decrease for this current 12-month fiscal period is -135.70%, and is forecasted to reach 0.47 in the upcoming year. Looking at the long run, market analysts have predicted that Company’s EPS will increase by 73.10% through the next 5 years, which can be compared against the 4.70% growth it accomplished over the previous five years trading on the market.
Additional Trading Performance Indicators
Now turning our attention to the current performance indicators for Ironwood Pharmaceuticals Inc., this organization’s Quick Ratio in the last reported quarter now stands at 2.00. The company has managed to achieve an average true range (ATR) of 0.38. Alongside those, its Beta score is 1.75.
Another valuable indicator worth considering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 3.64 for this organization.
In the same vein, IRWD’s Diluted EPS (Earnings per Share) trailing twelve months was posted at -1.30, a figure that is expected to reach 0.09 in the next reported quarter, and analysts expect it will be 0.47 at the market close of one year from today’s date.